Dr. Bekelman leads research programs in cancer health services, comparative effectiveness and delivery system and payment reform. His research integrates methods from the fields of epidemiology, clinical trials, health economics and public policy. Dr. Bekelman conducts research to examine the quality, comparative effectiveness, and costs of treatments for prevalent cancers using registry, Medicare, and commercial payer administrative claims data and co-leads the multicenter PARTIQoL randomized trial, which compares patient-reported outcomes after proton therapy versus intensity-modulated radiotherapy (IMRT) for prostate cancer. Dr. Bekelman has received research funding from the National Cancer Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Dr. Bekelman formerly served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
2014. Getting the Next Version of Payment Policy "Right" on the Road Toward Accountable Cancer Care. Int J Radiat Oncol Biol Phys. In press.
2014. Principles and Reality of Proton Therapy Treatment Allocation Int J Radiat Oncol Biol Phys.
2014. Reference Pricing with Evidence Development-A Way Forward for Proton Therapy. Journal of Clinical Oncology. 32(15):1540-2.
2013. Toward Accountable Cancer Care. JAMA Internal Medicine 173(11): 958-9, June.
2013. Single vs Multiple Fraction Radiotherapy for Bone Metastases from Prostate Cancer. JAMA 310(14): 1501-02, Oct.
2013. Effect of Practice Integration between Urologists and Radiation Oncologistson Prostate Cancer Treatment Patterns. Journal of Urology 190(1): 97-101, Jul.
2013. Radical Cystectomy versus Bladder Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Bias in Cancer Observational Comparative Effectiveness Research. Value in Health 16(4): 610-8, Jun.
2011. Implications of Comparative Effectiveness Research for Radiation Oncology. Practical Radiation Oncology 1(2): 72-80.
2011. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81(4): e325-34.
2003. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465.
©2011-2012 The Trustees of the University of Pennsylvania. Site by P’unk Ave.